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Background and Objectives Plasma pools for the production of human plasma
medicinal products are distinguished according to the collection method (recovered
or apheresis plasma) and the donor remuneration status. National regulations and
the physical status of the donor determine the donation frequency and plasma
volume per session. Relevant protein contents of different types of pools have not
fully been compared.
Materials and Methods We compared the levels of total protein, 15 main relevant
plasma protein markers, and anti-B19 and anti-Streptococcus pneumoniae IgG in
single-type pools of donations from different countries (Belgium, Finland, France,
the Netherlands, Germany, United States). Both recovered plasma from non-remu-
nerated donors and apheresis plasma from remunerated and non-remunerated
donors were studied.
Results Pools from paid US high-frequency, high-volume plasmapheresis donors
showed signiﬁcantly lower total protein ()9%), albumin ()15%), total IgG ()24%),
IgM ()28%), hemopexin ()11%) and retinol-binding protein ()10%) but higher C1-
inhibitor, pre-albumin and C-reactive protein contents than pools from unpaid
European Union (EU) or US whole-blood or plasmapheresis donors. In contrast to
pools from compensated EU plasmapheresis donors, pools from unpaid whole-blood
or plasmapheresis donors showed no signiﬁcant differences, whatever the collection
method or country. Reductions in speciﬁc protein contents correlated well with
protein half-life.
Conclusion These results should be taken into account with regard to donor health
management and protein recovery.
Key words: albumin, donor remuneration, immunoglobulin, plasma donors, plasma
fractionation, proteins.
Introduction
Human plasma-derived medicinal products are essential
medicines for the treatment of patients with serious life-
threatening chronic diseases and disorders [1]. Their pro-
duction from plasma requires thoroughly appropriate
donor selection, serological and microbiological donation
screening, and pharmaceutical processing of plasma pro-
teins. Plasma types can be classiﬁed according to the
method of collection: recovered vs. apheresis (source)
plasma, standard vs. hyperimmune plasma. Plasma types
can also be distinguished according to the remuneration
status of the donor (paid, compensated, or unpaid). Recov-
ered plasma is produced by separating donated whole
blood into cellular components and plasma. Source
plasma is collected through apheresis, a process that takes
only plasma from the donor while the cellular components
are returned. Donation by plasmapheresis can be per-
formed more frequently than whole-blood donation, as
the body replaces the volume of donated plasma much
faster than the volume of donated cellular components.
Apheresis plasma can also be obtained as a by-product of
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220platelets: in this case only the red cells are returned to the
donor. This contribution to the manufacturing plasma
pool is very low. Plasma derivatives are obtained through
industrial-scale processing of a large number of pooled
plasma donations. Plasma for fractionation must comply,
in Europe, with monograph 01⁄2005:0853 of the Euro-
pean Pharmacopoeia. About 18 different therapeutic pro-
teins are puriﬁed via a multi-step process including
precipitations and⁄or chromatographic steps. With global-
ization, the demand for pharmaceutical plasma products,
particularly intravenous immunoglobulin (IVIG) products,
is growing at the rate of 3–5% per annum [2–4]. There is
thus growing concern that a shortage of biological source
material might occur, resulting in failure to meet the full
demand for ﬁnal products. This risk of shortage is stimu-
lating discussions on the manufacturing yield of speciﬁc
proteins and also on methods for increasing plasma sup-
ply, including high-frequency, high-volume plasma dona-
tions and the payment of plasma donors. Recognition of
the importance of blood safety has led the World Health
Organization (WHO) [5], the US Food and Drug Adminis-
tration (FDA), the European Commission (EC), the Council
of Europe [Council Europe 2008], the International Red
Cross and Red Crescent Societies (IRCRCS), and the Inter-
national Society of Blood Transfusion (ISBT) [6]
to strongly discourage payment for whole blood. In
Germany, monetary compensation of expenses is permit-
ted for both apheresis and whole-blood donation [6]. The
commercial for-proﬁt fractionation industry, with its
attendant plasma collection centres, relies primarily
on paid donors, mostly living in the United States and
Germany. The fractionation sector in China, emerging
internationally, is also based on paid source plasma
collection. In contrast, non-proﬁt blood transfusion
organizations in both Europe and the United States
depend on the unpaid-donor network. Over the past
decade in the United States, substantial changes have
occurred with plasma source ‘rationalization’, i.e. a shift
from independent plasma collection centres to concentra-
tion of their ownership in the hands of four major interna-
tional fractionation companies [7].
The safety of paid- vs. unpaid-donor plasma is discussed
at length in publications and at meetings, and remains con-
troversial [8–11]. Plasma derivative safety relies on careful
donor selection, extensive donation screening, efﬁcient
virus inactivation⁄removal steps included in the manufac-
turing process, and strict application of GMP rules at all
stages of production. As a consequence of these measures,
no transmission of infectious blood-borne diseases by
plasma derivatives has been observed since 1997. The max-
imum volume of plasma to be donated and the donation
frequency are regulated by national authorities and differ
from country to country. For recovered plasma, the
authorized volume ranges from 450 (±10%) to 500 (±10%)
ml⁄donation, anticoagulant excluded. For apheresis plasma
it ranges from 400 to 800 ml⁄donation, anticoagulant
excluded. The donation frequency ranges from 3 to
5 times⁄year for whole blood and from 15 to 104 times⁄
year for plasma.
Both source plasma and recovered plasma are known
to be appropriate for use as starting material for the
manufacture of plasma derivatives [1]. Differences have
been observed as regards the yield. Apheresis plasma col-
lected from donors undergoing frequent plasmapheresis
contains lower levels of IgG but higher concentrations of
clotting factors than plasma units produced by moderate
serial plasmapheresis or from whole blood [1]. Whereas
previous studies on intensive donor plasmapheresis have
focused on donor safety, few have considered the compo-
sition of the collected plasma itself. In this study, we
have compared the levels of various plasma proteins in
plasmas for fractionation obtained by pooling of dona-
tions from either compensated (Group III) or paid (Group
IV) donors with the levels observed in plasmas collected
from unpaid donors (Groups I and II). The donations were
collected in different countries and each pool studied was
composed of donations from a single country. The
proteins studied were chosen because they are key physi-
ological proteins (hemopexin, immunoglobulin A, trans-
ferrin, IgM), inﬂammatory proteins [a-acid glycoprotein,
C-reactive protein (CRP)], nutritional index proteins
[retinol-binding protein (RBP) and prealbumin] or
therapeutic proteins (albumin, immunoglobulin G,
C1-inhibitor).
We have further investigated in what way this informa-
tion might contribute to better understanding of donor
safety in relation to donor vigilance.
Materials and methods
Donors and plasma donations
All donations were taken from suitable donors between
February 2006 and January 2008. Individual donations
were tested. Whole-blood units and apheresis plasma were
collected into anticoagulant-preservative solution accord-
ing to the European Pharmacopoeia, FDA, and AABB
guidelines. The plasmas were processed by established by
authorities recognized local blood transfusion centres
(BTCs) in the European Union (EU, speciﬁcally in Belgium,
Finland, France, Germany and the Netherlands) and in the
continental United States (10 different centres at different
locations). Processing was performed routinely, according
to the established local procedures and speciﬁcations and
in compliance with national regulations. Recovered and
source plasma donations were tested and found to be
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bodies and HBsAg. Screening for anti-HTLVI⁄II antibodies
was performed in Finland, the Netherlands, France and
the United States according to national regulations.
Nucleic acid technology (NAT) was used to test all dona-
tions for HIV1⁄2-RNA and HCV-RNA. Donations were
also screened for HBV-DNA in Finland, the Netherlands,
Germany and the United States. West Nile Virus was
tested by NAT in US recovered plasma. Usually the dona-
tions destined for fractionation were additionally screened
for Erythrovirus genotypes 1 & 2 (parvovirus) B19 DNA
and HAV RNA on mini-pools. When the mini-pools
were found positive, they were deconstructed and the
positive donations rejected. The limit is < 10
4 IU B19⁄ml
in the manufacturing plasma pools (European Pharma-
copoeia) [12].
The donors were healthy, voluntary and motivated. In
Europe, they were mostly unpaid, in accordance with the
Council of Europe criteria [13], or compensated [6]. In the
United States, they were unpaid (recovered plasma col-
lected at one BTC) or paid (source plasma from plasmaphe-
resis centres). The total plasma unit volume per donation
ranged from 280 to 320 ml for recovered plasma and from
581 to 814 ml for source plasma. All plasma donations
were stored frozen at < )20 to )30 C within 24 h of collec-
tion and during shipment, and the temperature was moni-
tored continuously. All donations were stored at )30 Ca t
CAF-DCF. Table 1 shows the donors’ respective countries
and remuneration statuses, the number of batches analysed,
and the mean donation volume.
Plasma pools and fractionation
All plasma pools were produced at the CAF-DCF (Brussels,
Belgium) plant according to a modiﬁed Cohn-Oncley pro-
cess adapted to its production. Brieﬂy, each starting
plasma pool (800–2700 l) for fractionation was produced
from only recovered plasma or only source plasma from
only one country. After the bags⁄bottles were cut, the
plasma was extruded, thawed (1 ± 0Æ5 C) and centrifuged
(Wesfalia BK28, Cha ˆteau Thierry, France) in a continuous
process. This step yielded the ﬁrst homogeneous plasma
pool (the cryosupernatant) and a cryoprecipitate rich in
Factor VIII.
All plasma pools were tested again for viral markers as
described earlier and found to be non-reactive. All plasma
pools complied with the speciﬁc monographs of the Euro-
pean Pharmacopoeia 5.0 [14].
A series of 50-ml cryosupernatant samples were taken
from each batch and immediately stored at )80 C.
Biochemical analyses
Total Protein
Total protein concentration was determined by the Biuret
method. The standard was an 8% human albumin provided
by Sanquin, Amsterdam, the Netherlands.
Speciﬁc plasma protein analyses
The concentrations of albumin (HSA), a1-acid-glycoprotein
(AGP), C1-inhibitor (C1-INH), hemopexin (HPX), immuno-
globulin G (IgG) and IgG subclasses (IgG1, IgG2, IgG3,
IgG4), immunoglobulin A (IgA), RBP, transferrin (TRF),
prealbumin (PREALB), CRP and IgM were measured by
nephelometry with a BN ProSpec apparatus (Dade Behring,
Marburg, Germany). A calibrated in-house plasma pool
standard was included in each run. The intra- and inter-run
coefﬁcients of variation (CVs) were < 6%, except for RBP
and C1-INH, where the CV was about 10%.
Speciﬁc anti-parvovirus B19 antibodies
After thawing, the homogeneous plasma pools (cryosuper-
natants) were ﬁrst diluted 200-fold in the kit buffer. Total
speciﬁc antibodies against the VP2 capsid protein of parvo-
virus B19 were measured by means of the ‘Parvovirus B19
IgG ELISA’ (Biotrin, Dublin, Ireland) according to the
supplier’s instructions. The assay was calibrated with the
WHO International standard 01⁄602 for anti-parvovirus
B19 (NIBSC, South Mimms, UK).
Table 1 Donors’ respective countries, number of batches and mean
donation volume
Group Remuneration
Method
collection
plasma
Number
batches
Mean plasma
volume per
donation (ml)
Group I
Finland Unpaid Recovered 6 288 ± 1
a
France Unpaid Recovered 3 320 ± 7
Germany Unpaid Recovered 2 306 ± 1
The Netherlands Unpaid Recovered 10 318 ± 2
Unpaid Source 10 634 ± 5
Belgium Unpaid Recovered 10 280 ± 2
Source 10 581 ± 7
Group II
United States Unpaid Recovered 5 317 ± 14
Group III
Germany Compensated Source 8 657 ± 95
Group IV
United States Paid Source 41 814 ± 13
Taking the plasma density (d =1 Æ024) in account, the volume per donation
for each batch is calculated as follows:
Total donations weight per batch – container weight⁄number of
donations per batch.
aMean of all batches ± standard deviation.
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Total anti-pneumococcal antibodies
Plasma pool samples were ﬁrst diluted 100- to 300-fold
in 8 mM Tris–HCl (pH 7Æ4) buffer containing 0Æ5% casein.
Total speciﬁc anti-pneumococcus antibody determina-
tions were performed with an enzyme-linked immuno-
sorbent assay (ELISA) (ELIZEN; Zentech, Lie `ge, Belgium)
according to the supplier’s recommendations. The coat-
ing antigen was a mix of the 23 most frequent pneumo-
coccus polysaccharides (serotypes 1, 2, 3, 4, 5, 6, 7F, 8,
9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A,
20, 22F, 23F, 33F). The cryosupernatant dilutions were
ﬁrst pre-incubated for 1 h at 37 C in the presence of
10 lg⁄ml C-polysaccharide (C-PS) (Statens Serum Insti-
tute, Copenhagen, Denmark) to increase the speciﬁcity of
the test according to the WHO manual [15]. The FDA⁄
CBER 89SF-5 pneumococcal reference serum was used
as standard [16].
Serotype-speciﬁc anti-pneumococcal antibodies
To measure the concentrations of IgG directed against ser-
otypes 10A, 18C, and 19A, the plasma was ﬁrst mixed
with C-PS absorbent and with the rare serotype 22F poly-
saccharide (LGS-ATCC Standards; Teddington, UK),
according to the WHO manual [15]. The 22F antigen was
added to avoid measuring cross-reacting antibodies capa-
ble of recognizing different pneumococcal serotypes. After
a 60-min pre-incubation, 100 ml of each plasma dilution
was added to microwells of a microtiter plate (MaxiSorp;
Thermo Fisher, Roskilde, Denmark) coated with the appro-
priate individual serotype polysaccharide (0Æ1 lg⁄well).
After 1 h at 37 C, the wells were washed with PBS-1%
Tween 20 (pH 7Æ4). After washing, the serotype-speciﬁc
antibody bound to the ELISA plate was detected with per-
oxidase-conjugated rabbit anti-human IgG antibody, fol-
lowed by addition of the substrate tetra-methylbenzidine
(Sigma Life Science, Bornem, Belgium). After a 30-min
incubation, the reaction was stopped with 1 M H2SO4 and
the optical density of each well was measured at 450 nm
with a Microplate reader 3550 (Biorad, Gent, Belgium). By
comparing the optical density in each sample well with
the optical densities of wells containing the standard
(human anti-pneumococcal reference serum, FDA⁄CBER
batch 89SF-5), the level of antibody in the plasma pools
was calculated.
Data and statistical analyses
All data management⁄analysis was carried out with Excel
and GraphPad Software, La Jolla, CA.
The speciﬁc anti-B19 and total anti-pneumococcus anti-
body concentrations were analysed following logarithmic
transformation. Results are expressed as geometric means
with standard deviations.
Statistical signiﬁcance was evaluated with Student’s
t-test. Differences with P-values below 0Æ05 were consid-
ered signiﬁcant and ones with P-values below 0Æ0001 were
considered highly signiﬁcant.
Results
Plasma types can be distinguished according to the method
of collection (recovered or apheresis plasma), the donor
remuneration status (paid, compensated or unpaid donors),
and according to whether the plasma is polyvalent or
hyperimmune regarding antibody content. In the present
study, we compared the plasma protein compositions of
recovered plasma and source plasma in fractionation pools,
each pool being made with donations collected within a
single country.
Donation plasma volume and anticoagulant
contribution
In the EU, the mean donation volume per unit was
302 ± 18 ml for recovered plasma and 608 ± 37 ml for
source plasma (Group I donors) (Table 1). The mean dona-
tion volume collected from German Group III donors was
657 ± 95 ml source plasma⁄unit. In the United States, the
mean source plasma donation volume per unit was
814 ± 13 ml, i.e. 34% higher than for Group I donors and
24% higher than for Group III donors.
Depending on the type of collection, different anticoagu-
lants are used. In this study, all the recovered plasma dona-
tions contained the same anticoagulant, citrate-phosphate
dextrose used at the same concentration (14⁄100 ml col-
lected whole blood). For apheresis plasma donations, in
most cases, the anticoagulant used was 4% sodium citrate in
a 1:16 (6Æ3 ml anticoagulant for 100 ml blood) ratio. Some
apheresis donations collected in the Netherlands and Bel-
gium included the anticoagulant citrate-dextrose A (ACDA)
(9–11 ml anticoagulant⁄100 ml blood). Taking in account
the haematocrit for calculation and experimental data
(H. Vrielink, J. Carlisle; personal communication), it results
that apheresis plasma is less diluted than recovered plasma.
Protein distribution between cryoprecipitate
and cryosupernatant
The process of plasma thawing and centrifugation was con-
tinuous, with a ﬂow rate of 500 l⁄h, leading to a ﬁrst
homogeneous plasma pool, the cryosupernatant and a
cryoprecipitate. As expected, 98% of the total protein and
99% of the speciﬁc plasma proteins analysed were found in
the cryosupernatant (data not shown).
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vs. EU source plasma (Group I)
Recovered and source plasma donations were collected
from Group I donors in ﬁve European countries (Finland,
France, Germany, the Netherlands, and Belgium). Each
plasma pool was produced with only one type of plasma
donation from a single country. Thirty-one plasma pools
were assembled with recovered plasma and 20 with source
plasma (Table 1). The studied parameters were ‘total
protein’, albumin (HSA), total IgG, IgM, IgA, TRF, HPX,
a1-glycoprotein (AGP), RBP, C1-inhibitor (C1-INH), pre-
albumin (PREALB) and CRP. These parameters were
selected because of the following reasons: albumin and
IgG (in intramuscular, subcutaneous and IVIG) are major
medicinal plasma-derived products as is C1-INH, an active
anti-inﬂammatory serine protease inhibitor, effective in
the complement, contact and clotting systems. The levels
of IgG and IgM are considered to be indicators of the
humoral immune status. TRF is a key protein in the iron
transport system. AGP and CRP are relevant to acute-
phase inﬂammation. HPX is a scavenger of the toxic
heme released or lost by heme proteins such as haemoglo-
bin. IgA and PREALB are the proteins studied in long-
term plasmapheresis [17]. RBP, a protein with a short
plasma half-life (12 h), and PREALB has also been advo-
cated as indicators of protein status in nutritional assess-
ment [18].
The individual data for each batch are presented in
Fig. 1 for the markers ‘total protein’, HSA, IgM and C1-
INH. Table 2 shows that the contents in total protein and
11 different proteins were very reproducible from batch to
batch for recovered and source plasma. For most markers,
batch variability was always < 10%, but it exceeded 17%
for CRP.
Table 2 also shows that no difference (P >0 Æ05) was
observed for any tested protein marker between plasma
pools made with recovered plasma and source plasma.
Moreover, no difference (P >0 Æ05) was found between
plasmas collected in the different EU countries (datanot
shown). These data were therefore combined (Group I)
for subsequent comparison with US plasma pools.
Pools of EU plasma (Group I) vs. US recovered
plasma (Group II)
Five individual pools of recovered plasma collected in the
United States (Group II) were analysed for the same 11 pro-
tein markers (see Table 2). Again a great homogeneity of
total and speciﬁc proteins was observed from batch to
batch (except for RBP). No signiﬁcant differences were
detected between EU plasma (Group I) and US recovered
plasma (Group II). These results seem to rule out any signif-
icant differences in plasma protein content between dona-
tions collected in countries with ethnically different
populations.
Pools of US Group IV source plasma vs. EU Group I
plasma pools
The results are shown in Tables 3 and 4 and in Figs 1 and 2.
Forty-one plasma pools produced with US source plasma
(Group IV) were individually analysed for their content in
total protein and in 11 different speciﬁc proteins. The
results were compared with those obtained for 51 EU
plasma pools (Group I).
(a)
(c) (d)
(b)
Fig. 1 Total protein, albumin, IgM and C1-
inhibitor contents of individual plasma pools
collected from Group-I, Group-II, Group-III and
Group-IV donors. Total protein (A), albumin (B),
IgM (C) and C1-inhibitor (D) contents, expressed
in g⁄l, were determined in individual batches
according to Materials and Methods. Each
plasma pool was produced from one type of
plasma: Group I donors (o) (51 batches), Group II
donors (d) (ﬁve batches), Group III donors (h)
(eight batches) and Group IV donors (D)( 4 1
batches). Each symbol represents one individual
batch. The horizontal line (-) represents the
mean of all batches of the speciﬁed type.
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The results are shown in Table 3 and Fig. 1. The total and
speciﬁc protein contents did not vary much from batch to
batch produced with Group IV donations. Except for AGP,
both the total protein concentration and the speciﬁc plasma
protein concentrations were signiﬁcantly lower in the US
source plasma pools, but to different extents. On the aver-
age, total protein was 9% lower than in EU plasma, RBP
was 10% lower, and TRF was 7% lower. Although statisti-
cally signiﬁcant, the difference found for IgA between the
two types of plasma pools can be considered negligible
()6%).
Much lower in the US source plasma pools were the HPX
()11%), albumin ()15%), IgM ()28%) and total IgG ()24%)
contents. Analysis of the individual data for the 41 US
batches indicated that most of the batches contained total
IgG levels ranging from 5Æ67 to 7Æ84 g⁄l, with seven
batches (17%) containing < 6 g⁄l (Fig. 1). In contrast, in
98% of the EU batches, the total IgG concentration ranged
from 7Æ11 to 9Æ82 g⁄l. The albumin content in the US
batches ranged from 22Æ8t o3 3 Æ3g⁄l, with 22 batches
(53%) containing < 30 g⁄l. Except for one batch, the EU
batches had an albumin concentration ranging from 31Æ4t o
40 g⁄l. The IgM content in US paid donation pools ranged
from 0Æ52 to 0Æ96 g⁄l in contrast to the US Group II plasma
(range 1Æ07–1Æ17 g⁄l) and EU Group I plasma (range 0Æ74–
1Æ34 g⁄l).
The C1-INH, PREALB and CRP contents were signiﬁ-
cantly higher, however, in the US batches than in the EU
batches (respectively, 12%, 9% and 21% higher).
c-immunoglobulin subclasses
To determine whether IgG subclasses were affected by the
lower total IgG amount in the US plasma pools (Group IV),
the IgG1, IgG2, IgG3 and IgG4 concentrations were mea-
sured and compared in the unpaid US (Group II) and EU
batches (Group I). As the total IgG recovery calculated by
summing the results for the individual IgG subclasses
exceeded 90% of the independently measured total IgG,
further comparison was possible. No signiﬁcant difference
was found between donations collected from EU (Group I)
and US Group-II donors. In the US plasma batches (Group
Table 2 Compared protein contents of pools of EU recovered plasma, EU
source plasma and US recovered plasma
Markers
Content (g⁄l) in pools made from
Group I
Recovered
plasma
n=3 1
A
Group I
Source
plasma
n=2 0
B
Group II
Recovered
plasma
n=5
C
Total protein 60Æ95 ± 2Æ35
a 59Æ89 ± 4Æ66 58Æ43 ± 0Æ47
Albumin 33Æ92 ± 1Æ69 34Æ26 ± 2Æ97 33Æ56 ± 1Æ24
Total IgG 8Æ56 ± 0Æ61 8Æ32 ± 0Æ58 8Æ41 ± 0Æ32
IgM 0Æ95 ± 0Æ13 0Æ98 ± 0Æ14 1Æ11 ± 0Æ04
IgA 1Æ62 ± 0Æ21 1Æ65 ± 0Æ22 1Æ67 ± 0Æ18
Transferrin 2Æ22 ± 0Æ16 2Æ24 ± 0Æ22 2Æ30 ± 0Æ07
Haemopexin 0Æ70 ± 0Æ05 0Æ70 ± 0Æ07 0Æ73 ± 0Æ03
a1 glycoprotein 0Æ66 ± 0Æ03 0Æ68 ± 0Æ05 0Æ77 ± 0Æ01
Retinol-binding protein 0Æ03 ± 0Æ01 0Æ03 ± 0Æ01 0Æ03 ± 0Æ01
C1 inhibitor 0Æ21 ± 0Æ01 0Æ21 ± 0Æ02 0Æ21 ± 0Æ01
Prealbumin 0Æ19 ± 0Æ02 0Æ20 ± 0Æ04 0Æ19 ± 0Æ01
C-reactive protein 1Æ64 ± 0Æ28 1Æ85 ± 0Æ28 2Æ18 ± 0Æ22
Pools (n = 31) of EU Group I (as deﬁned in Table 1) recovered plasma were
compared with pools (n = 20) of EU Group I source plasma (columns A and
B). Total protein and speciﬁc protein concentrations were determined as
described under Materials and Methods. Additionally, 5 pools of recovered
plasma (Group II) collected in the United States (unpaid donors) (C) were
compared with recovered plasma collected in the EU (A). Differences
proved to be non-signiﬁcant for each marker (P >0 Æ05).
aThe results are expressed as means of all batches ± standard deviation.
Table 3 Comparison of total protein and speciﬁc plasma protein contents
in plasma pools collected from Group I and Group IV donors (mean ± SD)
Protein (g⁄l)
Content in g⁄l in donations
%
Variation
a C
P-value
D
Group I
n=5 1
A
Group IV
n=4 1
B
Total protein 60Æ46 ± 3Æ46
b 55Æ20 ± 2Æ60 )9< 0 Æ0001
Albumin 34Æ05 ± 2Æ24 29Æ05 ± 3Æ08 )15 < 0Æ0001
Total IgG 8Æ48 ± 0Æ61 6Æ49 ± 0Æ51 )24 < 0Æ0001
IgM 0Æ96 ± 0Æ13 0Æ69 ± 0Æ09 )28 < 0Æ0001
IgA 1Æ64 ± 0Æ22 1Æ54 ± 0Æ18 )6< 0 Æ05
Transferrin 2Æ23 ± 0Æ18 2Æ06 ± 0Æ15 )7< 0 Æ0001
Haemopexin 0Æ70 ± 0Æ05 0Æ62 ± 0Æ06 )11 < 0Æ0001
a1 glycoprotein 0Æ67 ± 0Æ04 0Æ65 ± 0Æ07 )2> 0 Æ05
Retinol-binding
protein
0Æ03 ± 0Æ01 0Æ03 ± 0Æ01 )10 < 0Æ05
C1 inhibitor 0Æ21 ± 0Æ01 0Æ232 ± 0Æ02 +12 < 0Æ0001
Prealbumin 0Æ19 ± 0Æ03 0Æ21 ± 0Æ02 +9 < 0Æ0001
C-reactive
protein
1Æ72 ± 0Æ29 2Æ08 ± 0Æ67 +21 < 0Æ05
Batches of plasma pools collected from Group I donors (as deﬁned in
Table 1) (n = 51) (A) were compared with plasma pools from Group IV
donors (n = 41) (B). Total protein was estimated by the Biuret method.
Speciﬁc protein concentrations were measured by nephelometry (see
Materials and Methods).
aThe per cent variation of each marker, shown in column C, is expressed
with respect to the Group I plasma pool value (column A) taken as 100%
for each protein marker.
bThe data are expressed as means ± standard
deviations. P <0 Æ05 is considered signiﬁcant. P <0 Æ0001 is considered
highly signiﬁcant (column D).
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IgG1 and IgG4 concentrations were respectively, 27% and
26% lower (Table 4). A striking difference was found for
IgG2, whose average concentration in the US plasma
batches (Group IV) reached only 70% of that measured in
the EU plasma pools. Figure 2 shows the individual data for
all pools.
Content in speciﬁc antibodies against parvovirus B19
and Streptococcus pneumoniae
To evaluate the pathogen-neutralizing capacity of the
immunoglobulins, we measured the titres of antibodies
recognizing a virus, the parvovirus B19, and a bacterium,
Streptococcus pneumoniae.
The US batches (Group IV) showed a signiﬁcantly (26%)
lower concentration of anti-B19 antibodies than the EU
batches (Group I). When the titres were divided by the total
IgG concentration, however, there no longer appeared any
difference (Table 5).
The total speciﬁc anti-pneumococcal antibody titre was
36% lower in the US batches (Group IV) than in the EU
batches (Group I) (Table 5). When the titres were divided by
the total IgG concentration, a 17% difference remained. To
investigate whether the effect was similar for antibodies
against each speciﬁc serotype, the capacity to neutralize
each of three serotypes (serotypes 10A, 18C and 19A) was
evaluated individually. The anti-19A IgG concentration
turned out to be similar in both plasma pools, but the US
batches showed respectively, 29% and 52% lower anti-10A
and anti-18C levels. The difference was not signiﬁcant for
anti-10A and anti-19A antibodies when the titre was
divided by the total IgG concentration, but the difference
remained signiﬁcant (37%) for anti-18C.
Further studies were performed on ﬁve batches of recov-
ered plasma collected from US donors (Group II) to see
whether the reduced amount of speciﬁc anti-pneumococcal
antibodies measured in US plasma pools (Group IV) might
result from a different epidemiological distribution of sero-
types between the US and the EU. Table 5 does show a dif-
ference for anti-serotype 19A antibodies, whose level was
more than twice as high in US (Group II) vs. EU (Group I)
Table 4 Immunoglobulin G subclass contents of plasma pools collected
from Group I, II, III and IV donors
IgG subclass
(g⁄l)
Donors
Group I
n=5 1
Group II
n=5
Group III
n=8
Group IV
n=4 1
IgG1 4Æ67 ± 0Æ63
b 5Æ01 ± 0Æ11 3Æ66 ± 0Æ60 3Æ40 ± 0Æ66
% Variation
a +7% )22% )27%
P-value > 0Æ05 < 0Æ0001 < 0Æ0001
IgG2 2Æ57 ± 0Æ22 2Æ66 ± 0Æ06 2Æ14 ± 0Æ19 1Æ80 ± 0Æ17
% Variation +3% )17% )30%
P-value > 0Æ05 < 0Æ0001 < 0Æ0001
IgG3 0Æ34 ± 0Æ03 0Æ32 ± 0Æ03 0Æ31 ± 0Æ03 0Æ31 ± 0Æ02
% Variation )5% )8% )8%
P-value > 0Æ05 < 0Æ05 < 0Æ0001
IgG4 0Æ46 ± 0Æ05 0Æ45 ± 0Æ02 0Æ44 ± 0Æ03 0Æ34 ± 0Æ03
% Variation )1% )2% )26%
P-value > 0Æ05 > 0Æ05 < 0Æ0001
IgG subclass levels were determined in Group II (n = 5), Group III (n = 8),
and Group IV (n = 41) plasma pools and compared with those of Group I
plasma pools (n = 51).
aPercent variations with respect to Group I donation pool values taken as
100%.
bThe results are means of the tested batches ± SD. IgG subclass
contents were measured by nephelometry. P <0 Æ0001 is considered highly
signiﬁcant.
(a) (b)
(d) (c)
Fig. 2 IgG subclass contents of individual
plasma pools collected from Group-I, Group-II,
Group-III and Group-IV donors. IgG1 (A), IgG2
(B), IgG3 (C); and IgG4 (D) contents, expressed in
g⁄l, were determined in individual batches by
nephelometry (see Materials and Methods). Each
plasma pool was produced from one type of
plasma: Group I donors (o) (51 batches), Group II
donors (d) (ﬁve batches), Group III donors (h)
(eight batches) and Group IV donors (D)( 4 1
batches). Each symbol represents one individual
batch. The horizontal line (-) represents the
mean of all batches of the speciﬁed type.
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serotypes 10A and 18C.
Variation of protein contents with regard to protein
half-life and donation frequency
The different levels of proteins in Group-IV vs. Group-I and
Group-II donors suggest a relationship between the dona-
tion frequency and the donor capacity to replace these pro-
teins. This replacement reﬂects the cumulated capacity of
protein synthesis, depending strongly on the protein half-
life, and the distribution between the vascular and extra-
vascular compartments. Figure 3 shows that there exists, in
general, a good linear correlation between the half-life of
most of the proteins [18–23] and the decrease expressed as
a percentage of the level measured in pools from Group I
donors (R
2 =0 Æ71 if IgM is taken into account and
R
2 =0 Æ86 if IgM is excluded).
Pools of EU donor source plasma (Group III) vs. EU
donor plasma pools (Group I)
To better understand the correlation between protein con-
tent and half-life, we studied eight batches obtained from
Group III donors. In Germany, donors are permitted, as in
the United States, to donate twice weekly but up to an
annual maximum of 28Æ5 l (with anticoagulant) per year.
The results shown in Table 4 and Figs 1 and 2 indicate that
although the levels of four immunoglobulins (IgM, IgG1,
IgG2 and IgG3) among the 11 markers were still signiﬁ-
cantly lower than in Group I donors, they were higher than
in Group IV donors. The IgM decrease was 23% in Group III
donors vs. 28% in Group IV donors. For IgG1 the decrease
was 22% vs. 27%, and for IgG2 it was 17% vs. 30%. The
total protein concentration was lower by a signiﬁcant 6%
in Group III donors (vs. 9% in Group IV donors). Only the
C1-INH concentration was higher (6%) in Group III donors.
The PREALB and CRP levels were in the range found for
Group I donors.
The severely reduced plasma levels of IgM and IgG
observed in Group III donors strongly suggest an impact of
other, unknown factors, such as their distribution between
the vascular and extravascular compartments.
Discussion
As the demand for plasma products, mainly immunoglobu-
lins, increases globally, and as new therapeutic indications
emerge, it is necessary to ﬁnd an adequate response to a
strong and permanent demand for plasma. About 26Æ5
Table 5 Anti-B19 and anti-Streptococcus pneumoniae antibody concen-
trations in plasma pools obtained from Group I, II and IV donors
Antibody
speciﬁcity
Donors
Group I
A
Group II
B
Group IV
C
Conc. % Conc.
% vs.
A
a Conc.
% vs.
A
a
Parvovirus B19 n =5 1 n =4 1
IU⁄ml 32Æ2±3 Æ7 100 23Æ9±4 Æ6 )26*
IU⁄gI g 3 Æ8±0 Æ4 100 3Æ7±0 Æ7 )3
S. pneumoniae
Total serotypes n =5 1 n =5 n =4 1
lg⁄ml 35Æ4±2 Æ8
b 100 34Æ3±2 Æ7+ 1 2 2 Æ5±0 Æ6 )36*
lg⁄gI g
c 4Æ2±0 Æ3 100 4Æ1±0 Æ4+ 13 Æ5±0 Æ1 )17*
Serotype 10A n =1 0 n =5 n =3 1
lg⁄ml 1Æ4±0 Æ2 100 1Æ8±0 Æ3 +28 1Æ0±0 Æ3 )29*
lg⁄gI g 0 Æ17 ± 0Æ02 100 0Æ2±0 Æ04 +17 0Æ16 ± 0Æ04 )6
Serotype 18C n =1 0 n =5 n =3 1
lg⁄ml 1Æ1±0 Æ1 100 1Æ3±0 Æ2 +18 0Æ53 ± 0Æ2 )52*
lg⁄gI g 0 Æ13 ± 0Æ02 100 0Æ15 ± 0Æ03 +15 0Æ08 ± 0Æ03 )38*
Serotype 19A n =1 0 n =5 n =3 1
lg⁄ml 3Æ3±0 Æ5 100 7Æ0±2 Æ8 +112* 2Æ8±1 Æ0 )15
lg⁄gI g 0 Æ39 ± 0Æ06 100 0Æ84 ± 0Æ35 +115* 0Æ44 ± 0Æ16 +13
Speciﬁc anti-B19 and anti-pneumococcus antibody contents were
measured by means of a speciﬁc ELISA, as described under Materials and
Methods, in pools produced with Group I (A), Group II (B) or Group IV
plasma (C). The number of batches (n) analysed is indicated.
aRepresents the per cent of variation with respect to the level determined
for Group I plasma pools, taken as 100%.
bResults are expressed as
means ± SD for all plasma pools of each type.
cSpeciﬁc antibody contents
expressed per g total immunoglobulin (see Table 3). *P-value highly
signiﬁcant < 0Æ001.
Fig. 3 Speciﬁc plasma protein levels in Group II donors, expressed as
percentages of the values obtained for Group I donors. The level of each
protein measured in Group IV donor plasma pools is expressed as a
percentage of that determined for Group I donor plasma pools and plotted
as a function of the protein’s half-life (in days, as found in the literature
[18–23]). The goodness of ﬁt is 0Æ86 if the data for IgM are excluded and
0Æ71 if they are included.
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worldwide, including 14Æ5 million in the US and 6Æ4 million
in the EU [3]. Currently, 33% of all fractionated plasma is
recovered plasma and 67% is obtained by apheresis.
We have compared recovered plasma from European
(Group I) and US donors (Group II) and source plasma from
European donors (Group I), German donors (Group III), and
US donors (Group IV) to determine whether differences in
the concentrations of the most relevant plasma proteins
occur. The European countries included Belgium, Finland,
France, Germany and the Netherlands. Each batch con-
tained only one type of plasma from a single country. A
ﬁrst study, focusing on the European donor pools (Group I),
compared the albumin, total IgG, IgA, IgM, transferrin,
hemopexin, a1-glycoprotein, RBP, C1-inhibitor, prealbumin,
CRP, and total protein contents of 31 pools of recovered
plasma and 20 batches of source plasma. No signiﬁcant dif-
ference was detected between recovered and source plasma,
nor between countries where the plasma was collected. An
impact of the anticoagulant volume according to the type
of collection could be excluded, even though the anticoag-
ulant-to-blood ratio of collected whole blood was higher
than the ratio obtained in the apheresis process [24]. Our
results show that plasmapheresis donation as performed
currently in these European countries does not affect the
speciﬁc plasma protein content compared to whole-blood
donation. This ﬁnding encouraged us subsequently to con-
sider all these batches together in our comparison with the
US plasma batches. The Council of Europe (2008) [13]
recommends a standard whole-blood donation of 450 ml +
10% excluding the anticoagulant (no more than 13% of the
estimated total blood volume) and allows 4 (for females) to
6 (for males) standard whole-blood donations annually,
with a minimum interval of two months. This period is
amply sufﬁcient to allow the plasma proteins to be synthe-
sized and replaced and to reach again their physiological
levels. A similar policy has been adopted by the FDA for
whole-blood donations. A study of ﬁve different batches of
recovered plasma from US donors (Group II) and the EU
pools (Group I) revealed no differences between these
batches as regards their total protein content or the levels
of the 11 tested plasma proteins.
All 41 US plasma batches (Group IV) complied with the
speciﬁc monograph for ‘Human plasma for fractionation’
(European Pharmacopoeia), with a total protein content
above 50 g⁄l. A signiﬁcantly (9%) lower total protein con-
tent was found, however, compared to the EU plasma
batches (Group I). Lower levels of speciﬁc proteins were
also found in the US batches (Table 2), but among these,
three groups could be distinguished: 1) IgA and AGP, show-
ing no signiﬁcant difference; 2) TRF, RBP and HPX, with
levels up to 11% lower; and 3) albumin, IgM and total IgG,
with levels 15% to 28% lower.
The impact of long-term intensive plasmapheresis on
plasma quality is well recognized and concerns a reduction
of IgG, IgA, IgM, albumin and total protein [17,25,26].
However, the number of studies is limited because of the
difﬁculty of conducting a prospective study on the safety
of long-term plasmapheresis in donors [27]. Observed cases
of decreased plasma protein levels following a plasmaphe-
resis donation may result from differences in local regula-
tions with respect to the amount of plasma allowed to be
drawn, the time interval between two donations, and the
monitoring system used. In 2004, in European Directive
2004⁄33⁄EC, the volume of a plasma donation increased
from 650 ml (including the anticoagulant) to a maximum
of 750 ml (excluding the anticoagulant) per procedure,
with a maximum of 25 l (previously 15 l) per year, and
with a 48-h interval between two donations. The previous
more stringent rules are still in use in several EU countries
(maximum 15 l⁄year). The present German Guidelines
(2005) limit collection to 850 ml per session and up to
28Æ5l⁄year, including the anticoagulant, with a minimum
interval of 48 h between two donations. The FDA⁄CBER
Guidelines for Automated Plasmapheresis (1992) set a limit
based solely upon the body weight of the donor, from
690 ml (50–67Æ5 kg) to 880 ml (over 79 kg) including the
anticoagulant, the frequency being limited to twice a week
with a 48-h interval.
Hellstern et al. [28] compared 75 source plasma units
(875 ml) collected in the United States with 75 units of Ger-
man source plasma (720 ml). The median interval between
two donations was 5 days in the United States and 14 days
in Germany. Signiﬁcantly lower total IgG, Factor V
and Factor VIII levels were measured in the US donations.
Bechtloff et al. [29] conducted a prospective trial on a small
number of experienced plasmapheresis donors, who were
asked to switch from a moderate to a more intensive plas-
mapheresis donation regime (750 ml⁄session and at least
one per week) over a 3-year period. The donors showed sig-
niﬁcantly lower total protein, albumin and IgG levels than
non-donors. The authors suggested that intensive plasma-
pheresis might cause a dysproteinemia pattern similar to
that seen in the nephrotic syndrome. Recently, a prospec-
tive multicenter study on the safety of intensive plasma-
pheresis (720 or 850 ml per session) was performed,
recruiting 2860 highly selected experienced donors used
to donate 600 ml of plasma regularly over a 3-year period
(SIPLA I) [26]. Despite a high dropout rate (about 75% of
the total of donors), the results showed a signiﬁcant reduc-
tion in the levels of IgG and total protein, and 14% of the
donors had to be excluded because of a low plasma IgG
level (< 5Æ8g⁄l). This speciﬁc adverse event associated with
automated donor plasmapheresis led to planning a second
study (Siplan) including at least 60 000 donors with a
minimum of 6Æ09 g⁄l IgG [30].
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appear to be differently affected in US source plasma pools.
This ﬁnding suggests that these groups of proteins are
reconstituted in the human body at different rates because
of their different half-lives in plasma. Accordingly, a good
linear correlation was seen between these groups of pro-
teins and the half-lives of these proteins in plasma (Fig. 3).
IgA and AGP have half-lives of < 5 days, and their concen-
trations were similar in the EU and US batches. Levels of
the heme-binding protein HPX and of the iron-carrier pro-
tein TRF were respectively, 11% and 7% lower in the US
batches, and their half-lives are respectively, 7 and 8 days.
The two proteins HSA and total IgG have a low turnover
rate (plasma half-lives: approximately 15 and 23 days,
respectively). These data should be put in perspective with
regard to the high frequency of donation and greater plas-
mapheresis volume allowed under FDA⁄CBER rules. The
high frequency of collection and the high volume of maxi-
mum 800 ml twice a week does not allow a return to the
normal level. Consequently, the concentration is 15–24%
lower than expected.
To conﬁrm this hypothesis, our study was extended to
German donors (Group III), who are allowed to give a maxi-
mum of 28Æ5 l (including anticoagulant solution) per year.
Eight pools containing source plasma from German donors
were analysed for the same 12 markers. The results showed
that only the IgM, IgG1, IgG2 and IgG3 contents were
reduced. The strong reduction may be due mostly to less
efﬁcient antigenic stimulation resulting from the frequency
of, and short intervals between donations.
Further analysis of the IgG subclasses revealed in US
batches (Group IV) a severe deﬁcit in IgG1, IgG2 and IgG4
()27%, )30%, )26%, respectively), whose half-lives range
from 20 to 21 days [20]. The slightly reduced IgG3 content
might again be because of rapid turnover, based on a half-
life of 7 days. This ﬁnding that the replacement of IgG3 is
different from and faster than that of the other IgG sub-
classes should induce studies on its physiological function,
which is unknown. The lower levels of speciﬁc anti-B19
and anti-pneumococcal antibodies reﬂect, partly in the lat-
ter case, the lower total IgG content of US source plasma
batches (Group IV). Comparing the anti-B19 IgG titres of
manufacturing plasma pools prepared from either source
plasma or recovered plasma, Modrof et al. [31] found them
to differ signiﬁcantly, the titre being 28% higher in recov-
ered plasma. Two of the main indications for total immuno-
globulins (in IgG products such as IVIG) are primary
and secondary immunodeﬁciency, as the corresponding
patients are very susceptible to infectious diseases, notably
caused by the various S. pneumoniae serotypes [32]. We
have therefore measured titres of speciﬁc antibodies recog-
nizing the serotypes 10A, 18C and 19A. Concentrations of
speciﬁc anti-serotype-10A and anti-serotype-19A
antibodies were lower in the US batches (Group IV) because
of the lower total IgG content. As for the lower anti-sero-
type-18C titre, it cannot be attributed to an epidemiological
difference between the two continents, i.e. to different
pneumococcal serotype frequencies [33–35], as the titre of
anti-serotype 18C was not signiﬁcantly different in EU and
US recovered plasma pools, in contrast to the titre of anti-
serotype 19A. Serotype 19A is frequent in the US. Its higher
frequency in the United States than in Europe may explain
why the corresponding IgG was about twice as abundant in
the US plasma batches.
Interesting is the 10% lower concentration of RBP in the
US source batches. Because of its very short half-life (about
12 h), this speciﬁc retinol carrier protein, which belongs to
the lipocalin family, is affected by inﬂammation. In recent
years, plasma protein markers have been shown to be reli-
able indicators of nutritional status, in particular during
specialized nutrition support intervention. RBP (plasma
half-life: 12 h), TRF (half-life: 8 days) and albumin (half-
life: 15 days) have been selected as nutritional deﬁciency
indicators included in the Nutritional Risk Index, being rep-
resentative, respectively, of proteins with very short, short,
and long to extremely long half-lives [18]. Our results
invalidate the view that the body replaces the donated
plasma usually within 24–48 h if the donor keeps a healthy
diet [36]. The low plasma protein level observed in US
plasma donors (Group IV) might not be considered indica-
tive of any disease, but it shows the presence of a not com-
pletely healthy condition compared to non-donors or
Group I donors.
In the present study some proteins, on the contrary, were
found at higher concentrations in the US batches (Group
IV) than in the EU batches (Group I): C1-INH and PREALB
were respectively, 12% and 8Æ9% higher. CRP, a protein
associated with inﬂammation, was 21% higher in US
plasma but still below the pathological level.
Regarding donor vigilance, the relatively low level of
albumin in Group IV indicates that donors with an undiag-
nosed cardiovascular disorder, or at risk of developing one,
should be rejected as high-frequency, high-volume donors
to avoid oedema. Although our donor vigilance study did
not focus on this aspect, Seidel (2009) [37], discussing red
cell management during frequent plasmapheresis, under-
lined the little attention paid to the impact of blood loss for
blood sampling and additional loss of residual blood in the
bowl and tubing of the disposable set after the donor has
been disconnected from the machine. Donors frequently
have to be turned away from plasma donation because of a
too-low haematocrit⁄haemoglobin level. Without ﬂushing
with saline at the end of the procedure, an additional loss
occurs per annum of 1440 ml blood (equivalent to three
whole-blood donations) in Germany (where plasma donors
donate up to 40 times⁄year) and 3744 ml blood (equivalent
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States (where the donors may donate up to 104 times⁄year).
This ﬁnding should be studied further to prevent high-fre-
quency, high-volume plasmapheresis donors from donating
unintentionally an excessive amount of cellular compo-
nents on an annual basis.
Conclusion
Our ﬁndings show that signiﬁcant differences can be found
in plasma protein levels in plasmas collected with different
techniques and frequencies. Whether these signiﬁcant dif-
ferences have relevant health implications for the donors is
questionable. Physiologically, the differences in albumin
level between the EU plasma pool (Group I) and the US
source plasma pool (Group IV) should be studied more care-
fully. In particular, the lower albumin level in the US source
plasma donors (Group IV) might result in a lower osmotic
pressure leading possibly to oedema in older donors, donors
with an undiagnosed cardiovascular disorder, or donors at
risk of developing one.
The need to obtain IgG for manufacturing IVIG is the
driving force for high-frequency, high-volume source
plasma collection. Yet the physiological replacement of IgG
is relatively slow, and restoration of normal physiological
levels takes time. This raises the question of whether it
might be advisable to reduce the frequency so as not to
jeopardize the humoral health status of the donor.
For rational plasma collection with a view to meeting the
increasing demand for plasma products, it is necessary to
conduct further studies on the physiological effects of
drawing plasma from plasma donors, so as to avoid impair-
ing the health status of donors.
Acknowledgements
The authors are grateful to Be ´atrice Kips for her excellent
assistance. They thank Hans Vrielink, John Carlisle, Colin
Brown for their valuable comments, Ludo Baeten, Raf De
Paepe, Ghislain Debailleul and Geert Longin for their col-
laboration, providing samples and useful information.
References
1 WHO Expert Committee on biological standardization. Rec-
ommendations on the production, control and regulation of
human plasma for fractionation. In: WHO Expert Committee
on Biological Standardization. Fifty-sixth Report. Technical
Report Series, No. 941. Geneva, 2007: 189–264
2 Burnouf T: Modern plasma fractionation. Transfus Med Rev
2007; 21:101–117
3 Robert P: Global plasma demand in 2015. International Plasma
Protein Congress (IPPC 2009), 3–4 March 2009, Paris, France
4 Flood P, Wills P, Lawler P, Ryan G, Rickard KA: Review of Aus-
tralia’s Plasma Fractionation Arrangements. Chapter 2: Global
demand for plasma products, p 39 (2006). Available from:
http://www.health.gov.au/plasmafractionationreview
5 Expert Committee on Biological Standardization. Resolution
WHA 58.13. Blood safety: proposal to establish World Blood
Donor Day. In: Fifty-eight World Health Assembly. World
Health Organization, Geneva 24–28 October, 2005
6 Kretschmer V, Weippert-Kretschmer M, Slonka J, Karger R,
Zeiler T: Perspectives of paid whole and plasma donation; in
Vyas GN, Williams AE (eds): Advances in Transfusion Safety.
Dev Biol (Basel). Basel, Karger, 2005: vol 120, 101–111
7 Lamb M: Source plasma: future outlook. Transfusion 2009;
49:1520–1526
8 van der Poel CL, Seifried E, Schassberg WP: Paying for blood
donations: still a risk? Vox Sang 2002; 83:285–293
9 van der Poel CL: Remuneration of blood donors: new proof of
the pudding ? Vox Sang 2008; 94:169–170
10 Caspari G, Gerlich WH, Gu ¨rtler L: Paying for blood donations –
still a risk? Vox Sang 2003; 85:52
11 Kalibatas V: Payment for whole blood donations in Lithuania:
the risk for infectious disease markers. Vox Sang 2008; 94:209–
215
12 Thomas I, Di Giambattista M, Ge ´rard C, Mathys E, Hougardy V,
Latour B, Branckaert T, Laub R: Prevalence of human erythrovi-
rus B19 DNA in healthy Belgian blood donors and correlation
with speciﬁc antibodies against structural and non-structural
viral proteins. Vox Sang 2003; 84:300–307
13 European Committee (Partial Agreement) on Blood Transfusion
(CD-P-TS). Guide to the preparation, use and quality assurance
of blood components. 14 edn. Council of Europe, Strasbourg,
France, 2008
14 European Pharmacopeia 5.0. 01⁄2005:0853. Human plasma for
fractionation. 2005:1746–1747
15 WHO Pneumococcal serology reference laboratories Training
manual for ELISA for the quantiﬁcation of S. pneumoniae
serotype speciﬁc IgG (Pn Ps ELISA) (WHO11) http://www.
vaccine.uab.edu
16 Concepcion NF, Frasch CE: Pneumococcal type 22F polysac-
charide absorption improves the speciﬁcity of a pneumococcal
polysaccharide enzyme linked immunosorbent assay. Clin
Diagn Lab Immunol 2001; 8:266–272
17 Shanbrom E, Lundak R, Walford RL: Long-term plasmapheresis:
effects on speciﬁc plasma proteins. Transfusion 1972; 12:162–
167
18 Marshall WJ: Nutritional assessment: its role in the provision of
nutritional support. J Clin Pathol 2008; 61:1083–1088
19 Easton JA, Hardwicke J, Whitehead PH: The estimation of two
alpha1 glycoproteins (orosomucoid and another alpha1 acid gly-
coprotein)inhealth anddisease.JClin Pathol1962;15:585–590
20 Morell A: Pharmacokinetics of intravenous immunoglobulin
preparations. in Lee ML, Strand V (eds): Intravenous Immuno-
globulins in Clinical Practice. New York, Basel, Hong Kong,
Marcel Dekker, Inc., 1997: 1–18, Chapter 1
21 Quinlan GJ, Martin GS, Evans TW: Albumin: biochemical
properties and therapeutic potential. Hepatology 2005; 41:
1211–1219
230 R. Laub et al.
  2010 The Author(s)
Vox Sanguinis   2010 International Society of Blood Transfusion, Vox Sanguinis (2010) 99, 220–23122 Delanghe JR, Langlois MR: Hemopexin: a review of biological
aspects and the role in laboratory medicine. Clin Chim Acta
2001; 312:13–23
23 Immunologie. Caracte ´ristiques des Immunoglobulines. in Man-
uel Merck de diagnostic et the ´rapeutique, 2nd edn. Paris,
France, Editions d’Apre `s, 1994: 276
24 RunkelS,HaubeltH,HitzlerW,HellsternP:Thequalityofplasma
collected by automated apheresis and of recovered plasma from
leukodepletedwholeblood.Transfusion2005;45:427–432
25 Cohen MA, Oberman HA: Safety and long-term effects of plas-
mapheresis. Transfusion 1970; 10:58–66
26 Salvaggio J, Arquembourg P, Bickers J, Bice D: The effect of
prolonged plasmapheresis on immunoglobulins, other serum
proteins, delayed hypersensitivity and phytohemagglutinin-
induced lymphocyte transformation. Int Arch Allergy Appl
Immunol 1971; 41:883–894
27 Schulzki T, Seidel K, Storch H, Karges H, Kiessig S, Schneider S,
Taborski U, Wolter K, Steppat D, Behm E, Zeisner M, Hellstern
P; SIPLA study group: A prospective multicentre study on the
safety of long-term intensive plasmapheresis in donors (SIPLA).
Vox Sang 2006; 91:162–173
28 Hellstern P, Bach J, Haubelt H, Hitzler WE, Mathis S, Vogt A:
The impact of the intensity of serial automated plasmapheresis
and the speed of deep-freezing on the quality of plasma. Trans-
fusion 2001; 41:1601–1605
29 Bechtloff S, Tran-My B, Haubelt H, Stelzer G, Anders C,
Hellstern P: A prospective trial on the safety of long-term
intensive plasmapheresis donors. Vox Sang 2005; 88:189–195
30 Hellstern P: Regulatory environment of plasma collection in
Germany. International Plasma Protein Congress (IPPC 2009),
3–4 March 2009, Paris, France
31 Modrof J, Berting A, Tille B, Klotz A, Forstner C et al.: Neutral-
ization of human parvovirus B19 by plasma and intravenous
immunoglobulins. Transfusion 2008; 48:178–186
32 Schiff RI: Treatment of primary immunodeﬁciency diseases
with gammaglobulin. in Lee ML, Strand V (eds): Intravenous
Immunoglobulins in Clinical Practice. New York, Basel, Hong
Kong, Marcel Dekker, Inc., 1997: 175–192, Chapter 14
33 Di Giambattista M, Branckaert T, Verspecht Y, Laub R: Measur-
ing and interpreting levels of antibodies against major pneumo-
coccus serotypes in plasma pools and intravenous
immunoglobulins. XIIth Meeting of the European Society for
Immunodeﬁciency, 4–7 October 2006, Budapest, Hungary
34 Beall B, Mc Ellistrem MC, Gertz RE Jr et al.: Pre- and postvacci-
nation clonal compositions of invasive pneumococcal serotypes
for isolates collected in the United States in 1999, 2001, and
2002. J Clin Microbiol 2006; 44:999–1017
35 Jefferson T, Ferroni E, Curtale F, Rossi PG, Borgia P: Streptococ-
cus pneumoniae in wester Europe: serotype distribution and
incidence in children less than 2 years old. Lancet Infect Dis
2006; 6:405–410
36 PPTA. Frequently Asked Questions. http://www.pptaglobal.org/
faq/Default.aspx?print=y as seen on 21⁄01⁄2009
37 Seidel K: Red cell management during plasmapheresis. Interna-
tional Plasma Protein Congress (IPPC 2009), 3–4 March 2009,
Paris, France
Plasma pools from different sources: impact of frequency of donations 231
  2010 The Author(s)
Vox Sanguinis   2010 International Society of Blood Transfusion, Vox Sanguinis (2010) 99, 220–231